Daesung Microbiological Labs. Co., Ltd. (KOSDAQ:036480)
South Korea · Delayed Price · Currency is KRW 6,640.00
-10.00 (-0.15%)
At close: May 29, 2026
KOSDAQ:036480 Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 25,870 | 25,989 | 23,804 | 25,562 | 25,500 | 23,997 |
Other Revenue | -0 | -0 | -0 | -0 | -0 | -0 |
| 25,870 | 25,989 | 23,804 | 25,562 | 25,500 | 23,997 | |
Revenue Growth (YoY) | 10.50% | 9.18% | -6.88% | 0.24% | 6.26% | -3.24% |
Cost of Revenue | 19,617 | 19,669 | 19,872 | 20,857 | 20,855 | 18,404 |
Gross Profit | 6,252 | 6,320 | 3,932 | 4,705 | 4,645 | 5,593 |
Selling, General & Admin | 4,951 | 4,894 | 4,772 | 4,789 | 4,354 | 4,694 |
Amortization of Goodwill & Intangibles | 121.19 | 121.37 | 139.81 | 190.8 | 200.28 | 131.44 |
Other Operating Expenses | 89.87 | 89.33 | 88.62 | 87.27 | 82.98 | 122.37 |
Operating Expenses | 5,719 | 5,606 | 5,484 | 5,394 | 4,973 | 5,256 |
Operating Income | 532.91 | 714.27 | -1,552 | -689.01 | -327.52 | 337.11 |
Interest Expense | -596.02 | -605.12 | -846.16 | -892.67 | -512.58 | -277.53 |
Interest & Investment Income | 221.46 | 216.41 | 296.55 | 374.42 | 213.88 | 119.03 |
Earnings From Equity Investments | -38.7 | -38.7 | -27.7 | 36.39 | -14.6 | -4.97 |
Currency Exchange Gain (Loss) | 236.16 | -0.9 | 548.48 | 58.67 | 478.31 | 566.84 |
Other Non Operating Income (Expenses) | 37.34 | 30 | -6.56 | 30.83 | 205.01 | 95.4 |
EBT Excluding Unusual Items | 393.16 | 315.96 | -1,587 | -1,081 | 42.49 | 835.87 |
Gain (Loss) on Sale of Investments | -0.09 | -0.07 | -0.19 | -0.29 | -0.91 | - |
Gain (Loss) on Sale of Assets | 4.68 | 19.04 | 16.26 | -0.07 | 2,219 | 7 |
Pretax Income | 397.75 | 334.93 | -1,571 | -1,082 | 2,261 | 842.87 |
Income Tax Expense | -255.97 | -263.26 | 198.32 | -402.05 | 557.38 | -23.05 |
Net Income | 653.72 | 598.19 | -1,769 | -679.68 | 1,703 | 865.92 |
Net Income to Common | 653.72 | 598.19 | -1,769 | -679.68 | 1,703 | 865.92 |
Net Income Growth | - | - | - | - | 96.69% | -42.98% |
Shares Outstanding (Basic) | - | 4 | 4 | 4 | 4 | 4 |
Shares Outstanding (Diluted) | - | 4 | 4 | 4 | 4 | 4 |
EPS (Basic) | - | 157.42 | -465.62 | -178.86 | 448.21 | 227.87 |
EPS (Diluted) | - | 157.42 | -465.62 | -178.86 | 448.21 | 227.87 |
EPS Growth | - | - | - | - | 96.69% | -42.98% |
Free Cash Flow | 1,409 | 1,054 | 1,308 | -2,490 | -1,160 | -764.71 |
Free Cash Flow Per Share | - | 277.49 | 344.14 | -655.25 | -305.18 | -201.24 |
Gross Margin | 24.17% | 24.32% | 16.52% | 18.40% | 18.22% | 23.31% |
Operating Margin | 2.06% | 2.75% | -6.52% | -2.70% | -1.28% | 1.41% |
Profit Margin | 2.53% | 2.30% | -7.43% | -2.66% | 6.68% | 3.61% |
Free Cash Flow Margin | 5.45% | 4.06% | 5.49% | -9.74% | -4.55% | -3.19% |
EBITDA | 3,063 | 3,255 | 163.17 | 2,173 | 2,378 | 2,875 |
EBITDA Margin | 11.84% | 12.52% | 0.69% | 8.50% | 9.33% | 11.98% |
D&A For EBITDA | 2,530 | 2,540 | 1,715 | 2,862 | 2,706 | 2,538 |
EBIT | 532.91 | 714.27 | -1,552 | -689.01 | -327.52 | 337.11 |
EBIT Margin | 2.06% | 2.75% | -6.52% | -2.70% | -1.28% | 1.41% |
Effective Tax Rate | - | - | - | - | 24.66% | - |
Advertising Expenses | - | 153.45 | 149.24 | 176.8 | 51.04 | 122.44 |